Beam shines a light on phase 1/2 data with its base editing candidate for sickle cell disease ahead of a full presentation at ASH next month.

Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...

Plans to create a new burial ground, build 20 new homes in a village and convert a barn are some of the latest planning applications submitted to Maidstone council. An application has been put forward ...

Environmental advocates and community activists Tuesday supported a proposal to add data centers to the list of large ...

Copper, base metals drift ahead of US jobs data, Fed meeting The jobs data is expected to underscore signs of a softening labour market, just days after unemployment claims rose to their highest since ...